Among the compounds in this catalogue, nicotinamide riboside is the exception, and it is only honest to say so upfront. Most items here are synthetic peptides whose evidence base is preclinical. NR is the opposite: a form of vitamin B3 studied for decades, with dozens of randomised human trials and food-ingredient clearance in both the US and the EU. So the conversation is different too. The question is not "does this even work in humans" but something far more interesting: what exactly does it do, and why does the biomarker rise while function often does not?
What NR is, and why it has a story of its own
Nicotinamide riboside is nicotinamide joined to a ribose sugar, a precursor to NAD⁺, the coenzyme central to energy metabolism and to sirtuin and PARP activity. Curiously, the substance itself had been known since the 1940s, but it was only recognised as a vitamin in 2004, when the enzyme nicotinamide riboside kinase (NRK1) was described. It is the rare case of a long-known molecule being assigned its own metabolic pathway in retrospect.
NR versus NMN: an argument with less certainty than it appears
NR is constantly compared with NMN, its neighbour that differs by a single phosphate group. Marketing for both loves categorical claims about "direct cellular uptake". The reality is more careful. Work from 2016 showed that at the cellular level NMN is first converted to NR outside the cell and only then taken up, so both compounds converge on the same enzyme, NRK1.
And in 2025 a study complicated the picture further: a large fraction of oral NR and NMN is not absorbed intact at all, but broken down to nicotinamide, reprocessed by the gut microbiota, and used by the liver via the classical pathway. The practical takeaway for a reader is simple: if a vendor promises you that "NR goes straight into the cell and NMN doesn't", they are repeating a simplified and now outdated version.
The most important thing to know about the clinical data
Here NR offers something rare, it really has been tested in humans many times, and the result is telling. It splits into two very different halves.
NAD⁺ goes up, reliably. This replicates study after study: roughly a 60% increase in blood-cell NAD⁺, an elevated NAD⁺ metabolome in skeletal muscle even in older people. There is no doubt about this part.
The functional outcomes, mostly do not. And this is the most important thing that can be said about NR honestly:
- In obese, insulin-resistant men, 2000 mg/day for 12 weeks did not improve insulin sensitivity.
- In the same cohort, a separate analysis found no change in muscle mitochondrial respiration, content or structure.
- A six-week crossover trial showed a slightly higher fat-free mass and a shift in acetylcarnitine metabolism, but no effect on insulin sensitivity, mitochondria, blood pressure or inflammation.
So we have a compound that reliably does what it should at the level of biochemistry (raises NAD⁺) and yet mostly fails to deliver the expected functional result. That gap is not a reason to dismiss NR, it is the most interesting scientific question around it.
Where there is a signal after all
The exception is neurodegeneration. In a phase I Parkinson's trial, NR raised brain NAD, and in those whose levels actually rose, cerebral metabolism shifted alongside a mild clinical improvement. That is a preliminary result from a small study not designed to measure efficacy. So the test was scaled up: the large phase III NOPARK trial (400 patients, 52 weeks) completed recruitment and dosing in 2025. Its results are not yet published, and it is those, not metabolic promises, that will be the real test of the NAD⁺ hypothesis in humans.
Why "approved as a food" is not "proven to work"
NR holds GRAS (Generally Recognized As Safe, a U.S. food-safety status) status in the US and EFSA (European Food Safety Authority) novel-food authorisation in the EU. That is a genuine advantage on safety: toxicology and clinical data have surfaced no worrying signals at studied doses. But there is an easy trap here. Regulatory clearance of an ingredient means it is safe in defined amounts, it does not mean its efficacy against ageing, metabolism, or any condition has been proven. These are two different questions, and conflating them is a common mistake.
The bottom line, unvarnished
NR is a rare case in this catalogue: a well-studied, safety-characterised, regulatorily recognised compound with its own interesting biochemistry. And at the same time, a clear demonstration that raising a biomarker is far easier than changing physiology. The most honest position today: it raises NAD⁺ convincingly, the clinical data mostly do not confirm metabolic benefit in healthy people, and the main open hope, neurodegeneration, is still waiting on the NOPARK results.
The full technical breakdown with primary-source citations is in our wiki monograph on nicotinamide riboside. The compound as a research reagent is on its product page (currently by pre-registration); adjacent NAD⁺-pathway items are gathered in the NAD+ / metabolic longevity category.
Research use only (RUO). Not for human or animal consumption; not a medicine, food or cosmetic. The doses cited are from published research protocols and are not a recommendation.